09/07/2026 CSPC’s B7-H3 ADC SYS6043 secures Breakthrough Therapy Designation in China for platinum-resistant Ovarian cancer CSPC’s B7-H3 ADC SYS6043 secures Breakthrough Therapy Designation in China for platinum-resistant Ovarian cancer (Ref) CSPC Pharmaceutical's antibody-drug conjugate (ADC) SYS6043, targeting B7-H3, has received Breakthrough Therapy Designation from China’s NMPA for platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer as monotherapy...

08/07/2026 New independent-statistician analyses show DCVax-L survival benefit was underestimated New independent-statistician analyses show DCVax-L survival benefit was underestimated (Ref) Northwest Biotherapeutics presented updated survival data from the Phase 3 trial of DCVax®-L (dendritic cell-based vaccine) for glioblastoma (GBM) at the 2026 BNOS meeting. Survival benefit of DCVax-L was likely underestimated in the original trial analysis New analyses used individual patient-level data...

June 4th Week, 2026 Regulatory Updates 🎯 Pfizer's palbociclib (Ibrance; CDK4/6 inhibitor) has been approved in the US for use with trastuzumab (anti-HER2) ± pertuzumab (anti-HER2), and endocrine therapy as 1L maintenance Tx for HR+, HER2+ LA/M breast cancer following induction therapy (Ref 1) ❓ How is Ibrance positioned in the BC market landscape? 🎯 The US FDA approved Gilead Sciences’ sacituzumab govitecan-hziy (Trodelvy; TROP2 ADC) for the 1L Tx of unresectable LA/M TNBC, either as...